Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JHL1922 versus Pulmozyme safety and pharmacokinetic crossover study in healthy volunteers
NL-OMON46758Active, not recruiting
- Sponsor
- Eden Biologics, Inc.
- Start
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of dornase alfa in cystic fibrosis (CF) (2 arms), sponsored by Eden Biologics, Inc. Primary endpoint: Safety and tolerability similarity. Started Jan 2018; status: active, not recruiting.
02
Drugs
dornase alfa
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON46758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46758.